Societal CDMO (Societal CDMO) Change In Working Capital : $-4.01 Mil (TTM As of Dec. 2023)

View and export this data going back to 2014. Start your Free Trial

What is Societal CDMO Change In Working Capital?

Societal CDMO's change in working capital for the quarter that ended in Dec. 2023 was $-2.27 Mil.

Societal CDMO's change in working capital for the fiscal year that ended in Dec. 2023 was $-4.01 Mil.

It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement. Not by calculating the number changes in each periods' working capital (Total Current Assets minus Total Current Liabilities).

Societal CDMO Change In Working Capital Historical Data

The historical data trend for Societal CDMO's Change In Working Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Societal CDMO Change In Working Capital Chart

Societal CDMO Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Change In Working Capital

Get a 7-Day Free Trial

-10.52

11.65

5.68

-8.36

-4.01

Societal CDMO Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Change In Working Capital	Get a 7-Day Free Trial															0.69	-1.69	0.31	-0.36	-2.27

Societal CDMO Change In Working Capital Calculation

Change In Working Capital for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-4.01 Mil.

Working Capital is a measure of a company's short term liquidity or its ability to cover short term liabilities. It is defined as the difference between a company's current assets and current liabilities.

Changes in Working Capital is reported in the cash flow statement since it is one of the major ways in which net income can differ from operating cash flow. It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement.

Use Wal-Mart Stores Inc (Jan 2014, Annual Data) as an example: Source: Wal-Mart Stores Inc 2014-01-31 10-K from SEC

Consolidated Statements of Cash Flows	Fiscal Years Ended	January 31,	(Amounts in millions)
Cash flows from operating activities:	2014	2013	2012
Changes in certain assets and liabilities, net of effects of acquisitions:
Receivables, net	(566)	(614)	(796)
Inventories	(1,667)	(2,759)	(3,727)
Accounts payable	531	1,061	2,687
Accrued liabilities	103	271	(935)
Accrued income taxes	(1,224)	981	994

For 2014-01-31, add all the items under 2014 collum together, Change in Working Capital was (566) + (1,667) + 531 + 103 + (1,224) = $ (2,823) Mil.

Societal CDMO Change In Working Capital Related Terms

Thank you for viewing the detailed overview of Societal CDMO's Change In Working Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

Societal CDMO (Societal CDMO) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Societal CDMO Inc (NAS:SCTL) » Definitions » Change In Working Capital

Comparable Companies

Traded in Other Exchanges

N/A

Address

1 E. Uwchlan Avenue, Suite 112, Exton, PA, USA, 19341

Website

https://www.societalcdmo.com

Societal CDMO Inc is a bi-coastal contract development and manufacturing organization. It offers capabilities spanning pre-Investigational New Drug development to commercial manufacturing and packaging for a wide range of therapeutic dosage forms primarily focused on small molecules. The company also provides therapeutic development, end-to-end regulatory support, clinical and commercial manufacturing, aseptic fill/finish, lyophilization, packaging, and logistics services to the global pharmaceutical market.

Executives

Bryan M. Reasons	director	C/O IMPAX LABORATORIES, INC., 30831 HUNTWOOD AVENUE, HAYWARD CA 94544
Elena Cant	director	C/O SOCIETAL CDMO, INC., 1 E. UWCHLAN AVENUE, SUITE 112, EXTON PA 19341
Enloe J David Jr	director, officer: Chief Executive Officer
James Charles Miller	director	490 LAPP ROAD, MALVERN PA 19355
Wayne Weisman	director	490 LAPP ROAD, MALVERN PA 19355
William Ashton	director	C/O HARRISON CONSULTING GROUP, PO BOX 283, NEWTOWN SQUARE PA 19073
Winston J Churchill	director	C/O SCP PARTNERS, SUITE 300, 1200 LIBERTY RIDGE DRIVE, WAYNE PA 19087
Awm Investment Company, Inc.	10 percent owner	527 MADISON AVENUE, SUITE 2600, NEW YORK NY 10022
Mathew Paul Arens	director, 10 percent owner	C/O FIRST LIGHT ASSET MANAGEMENT, LLC, 3300 EDINBOROUGH WAY, SUITE 201, EDINA MN 55435
First Light Asset Management, Llc	director, 10 percent owner	3300 EDINBOROUGH WAY, SUITE 201, EDINA MN 55435
Laura L. Parks	director	C/O RECRO PHARMA, INC., 490 LAPP ROAD, MALVERN PA 29355
Michael Berelowitz	director	415 EAST 37TH STREET, APT 36C, NEW YORK NY 10016
Ryan David Lake	officer: Chief Financial Officer	KENSEY NASH CORPORATION, 735 PENNSYLVANIA DRIVE, EXTON PA 19341
Scp Vitalife Partners (israel) Ii, L.p.	10 percent owner	SUITE 190, 7 GREAT VALLEY PARKWAY, MALVERN PA 19355
Scp Vitalife Partners Ii Lp	10 percent owner	SUITE 190, 7 GREAT VALLEY PARKWAY, MALVERN PA 19355